Therefore, we provide evidence that BUB1 might serve as a new therapeutic CSCs-target in HCC, such as the BUB1-specific inhibitors, and contribute to better understanding the CSCs-related molecular mechanism of the metastasis and recurrence of HCC. This evidence concerns the gene BUB1 and hepatocellular carcinoma.